New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareAHK-Cu vs PT-141 (Bremelanotide)

AHK-Cu vs PT-141 (Bremelanotide)

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticAnti-Aging & Longevity
AHK-Cu
Sexual Health & Libido
PT-141 (Bremelanotide)
Summary
AHK-Cu is a copper tripeptide composed of alanine, histidine, and lysine chelated to copper. Distinct from GHK-Cu, AHK-Cu exhibits strong affinity for hair follicle receptors and demonstrates potent hair growth stimulation alongside wound healing and skin regeneration properties.
PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
Half-Life
Hours (topical, variable by formulation)
2–3 hours
Admin Route
Topical, Scalp application, Subcutaneous (research)
SubQ
Research
Typical Dose
0.01–0.1% concentration
0.5–1.75 mg
Frequency
Once or twice daily
As needed (not daily)
Key Benefits
  • Stimulates hair follicle growth and reduces shedding
  • Increases dermal papilla cell proliferation
  • Promotes wound healing and skin regeneration
  • Antioxidant protection via superoxide dismutase activation
  • Improves skin elasticity and firmness
  • Supports collagen and elastin production
  • Enhances sexual desire and libido in both men and women
  • Improves arousal through central nervous system activation
  • Effective for psychological erectile dysfunction
  • Works for female sexual arousal disorder
  • May improve sexual satisfaction and intensity
  • Fast-acting — effects within 45–60 minutes
  • FDA-approved for HSDD in premenopausal women
Side Effects
  • Generally well-tolerated topically
  • Mild scalp irritation or redness in sensitive individuals
  • Possible temporary hair shedding phase at treatment initiation
  • Copper accumulation with excessive systemic use (rare)
  • Nausea (most common — 40% of users in clinical trials)
  • Facial flushing and warmth
  • Transient blood pressure changes (typically increase then normalize)
  • Headache
  • +2 more
Stacks With